Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report

CIC-rearranged sarcoma (CRS) is a subgroup of small round blue cell tumors similar to Ewing's sarcoma but lacking the EWSR1 gene translocation. It is characterized by a CIC gene rearrangement on chromosome 19q13, with the most common partner gene being DUX4. In 2021, the WHO classification of central nervous system tumors (5th edition) introduced a new pathological classification for CRS based on bone and soft tissue tumor classifications, categorizing it as mesenchymal non-meningeal epithelial tumors. Primary CIC::DUX4 rearrangement sarcoma in the central nervous system is extremely rare, with no established standard treatment and a very poor prognosis. Herein, we present a case of intracranial CIC::DUX4 rearrangement diagnosed using DNA methylation classifiers and multiple omics diagnosis techniques. We also document the disease progression after chemoradiation therapy and subsequent <i>in situ</i> recurrence.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-01-26
DOI
https://doi.org/10.3389/fonc.2025.1545700
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report

K. K. Li, Houshi Xu, Qisheng Tang, Huihui Chai et al.
Frontiers in Oncology
Sarcoma Diagnosis and Treatment
article

Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report

K. K. Li, Houshi Xu, Qisheng Tang, Huihui Chai, Maoyuan Sun, Z Y Shi, Bei-Ning Liu, Jingqi Hu, Rui-Ze Zhu, Yue Wang, Yun Guan, Shan Jiang
article en

Abstract

CIC-rearranged sarcoma (CRS) is a subgroup of small round blue cell tumors similar to Ewing's sarcoma but lacking the EWSR1 gene translocation. It is characterized by a CIC gene rearrangement on chromosome 19q13, with the most common partner gene being DUX4. In 2021, the WHO classification of central nervous system tumors (5th edition) introduced a new pathological classification for CRS based on bone and soft tissue tumor classifications, categorizing it as mesenchymal non-meningeal epithelial tumors. Primary CIC::DUX4 rearrangement sarcoma in the central nervous system is extremely rare, with no established standard treatment and a very poor prognosis. Herein, we present a case of intracranial CIC::DUX4 rearrangement diagnosed using DNA methylation classifiers and multiple omics diagnosis techniques. We also document the disease progression after chemoradiation therapy and subsequent <i>in situ</i> recurrence.

Frontiers in OncologyVol. 15
Chinese University of Hong Kong (HK), Fudan University (CN), Ohkawara Neurosurgical Hospital (JP), Shanghai Clinical Research Center (CN), Huashan Hospital (CN)
Shanghai Municipal Health Commission, National Natural Science Foundation of China, Fudan University, Science and Technology Commission of Shanghai Municipality, National Key Research and Development Program of China
No poverty
Openalex Percentile: Top 78%
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report — K. K. Li, Houshi Xu, et al. · Frontiers in Oncology (2026) | TGRS Research Map | TGRS